NPC1 and amyotrophic lateral sclerosis: Therefore, the authors have concluded that cholesterol homeostasis is dysregulated in ALS muscle from the presymptomatic stage and that targeting NPC1/2 alterations may represent a new therapeutic approach for patients affected by ALS [152].